Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT06848530
Status
Recruiting
Apply to this trial

Conditions

  • Movement Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Prescribed Medications — OTHER
    participant's movement disorders medications, prescribed by their treating physician
  • Deep brain stimulation adjustment — OTHER
    Deep brain stimulator parameters may be adjusted within normal clinical limits

Study Details

The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and/or through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.

Key Dates

Start date
Dec 10, 2025
Status verified
Mar 2026
Primary completion
Apr 30, 2030
Completion
Apr 30, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Participants without Deep Brain Stimulators
    Multimodal neurophysiology (for example, electroencephalography and electromyography) will be measured during the following: Movement disorder medication administration -The patient's movement disorders medications, prescribed by their treating physicians outside of this study, may be administered during an experimental session.
  • Experimental: Participants with Deep Brain Stimulators
    Multimodal neurophysiology (for example, electroencephalography and electromyography) will be measured during the following: Movement disorder medication administration -The patient's movement disorders medications, prescribed by their treating physicians outside of this study, may be administered during an experimental session. Deep brain stimulator (DBS) adjustment - Participants who have had deep brain stimulation implantation as part of their standard-of-care clinical treatment may participate in this study. The patient's stimulator may be adjusted within normal clinical limits during an experimental session.

Primary Outcome Measure

Neural signal biomarkers [ Time Frame: 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Pennsylvania HospitalPhiladelphiaPennsylvania19107
Charlotte Abeshaus
[email protected]
215-746-4850
Lauren Hammer, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
Pennsylvania Hospital· Philadelphia, PA

Related Studies